---
document_datetime: 2026-01-23 09:17:13
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/steqeyma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: steqeyma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.6244026
conversion_datetime: 2026-01-26 20:54:04.678773
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.70.0
  docling-core: 2.60.2
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Steqeyma

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II /  | This was an application for a group of | 11/12/2025                          |                                             |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000293190   | variations.   |
|---------------------|---------------|

<div style=\"page-break-after: always\"></div>

|                                       | variation - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test method - Accepted                                                                                                                                                                                                                                                                                                 |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000292238 | This was an application for a group of variations. B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Other changes - Accepted B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an | 11/12/2025 | SmPC, Labelling and PL | The SmPC has been updated to reflect the new pre- filled pen presentations, the updated storage conditions, the extended shelf-life, and to include a Polysorbate warning statement in line with the guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'. The Labelling and PL have been updated accordingly. Additionally, a correction has been introduced to the PL. |

<div style=\"page-break-after: always\"></div>

| B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.c Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| B.II.e.1.b Change in type of container or addition of a new container - B.II.e.1.b.2 Sterile medicinal products and biological/                                                                                                                            |
| protocol - Accepted                                                                                                                                                                                                                                        |
| B.II.b.1 Replacement or addition of a                                                                                                                                                                                                                      |
| manufacturing site for part or all of the manufacturing process of the finished                                                                                                                                                                            |
| product - B.II.b.1.a Secondary packaging                                                                                                                                                                                                                   |
| B.II.d.1 Change in the specification                                                                                                                                                                                                                       |
| parameters and/or limits of the finished                                                                                                                                                                                                                   |
| product - B.II.d.1.c Addition of a new                                                                                                                                                                                                                     |
| the specification with its corresponding test method -                                                                                                                                                                                                     |
| specification parameter to                                                                                                                                                                                                                                 |
| Accepted                                                                                                                                                                                                                                                   |
| parameters and/or limits of the finished                                                                                                                                                                                                                   |
| product - B.II.d.1.c Addition of a new                                                                                                                                                                                                                     |
| specification parameter to the specification                                                                                                                                                                                                               |
| with its corresponding test method -                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                                          | Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted                                                                                                                                                                             |            |     |      |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation type IA_IN / EMA/VR/0000312582 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted                                                                                                                                                                                | 17/11/2025 | N/A |      |
| Variation type IB / EMA/VR/0000306826    | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.c Other changes to a test procedure (including replacement or addition) for a reagent, which does not have a significant effect on the overall quality of the active substance - Accepted | 31/10/2025 | N/A |      |
| Variation type IB / EMA/VR/0000294529    | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                                       | 23/09/2025 |     | SmPC |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000280935   | This was an application for a group of variations. C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.2.a - To update sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC to extend the indication to include treatment of moderately to severely active Crohn's disease in paediatric patients weighing at least 40 kg, to align the PI with the same changes approved for the reference product Stelara. The package leaflet and RMP are updated accordingly. In addition, the MAH has taken the opportunity to update the details of the local representative for Sweden. C.I.11.z - To align the RMP with the latest approved RMP of duplicate product Qoyovlma in order   | 06/08/2025   | 11/09/2025   | SmPC and PL   |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|

<div style=\"page-break-after: always\"></div>

|                                       | to align the dossiers of the two products.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000272089 | This was an application for a group of variations. B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where | 24/07/2025 | N/A |
| Variation type II / EMA/VR/0000263478 | This was an application for a group of variations. B.II.b.5 Change to in-process tests or limits applied during the manufacture of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 24/07/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | finished product - B.II.b.5.e Widening of the approved IPC limits, which may have a significant effect on overall quality of the finished product - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.e Change outside the approved specifications limits range - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000272410 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update sections 4.5, 4.8 and 5.2 of the SmPC to add drug-drug interaction information based on results from study CNTO1275CRD1003 and to include patient exposure numbers based on results from study CNTO1275UCO3001 following assessment of the same change for the reference product Stelara. In addition, the MAH took the opportunity to implement editorial changes across the PI, including an amendment to the description of liquid | 12/06/2025 | 11/09/2025 | SmPC and PL | To update sections 4.5, 4.8 and 5.2 of the SmPC to add drug-drug interaction information based on results from study CNTO1275CRD1003 and to include patient exposure numbers based on results from study CNTO1275UCO3001 following assessment of the same change for the reference product Stelara. In addition, the MAH took the opportunity to implement editorial changes across the PI, including an amendment to the description of liquid dripping when the needle cap is removed from the Pre-filled Syringe device. |

<div style=\"page-break-after: always\"></div>

| dripping when the needle cap is removed from the Pre-filled Syringe device. These changes apply to all languages. Further editorial changes, such as the correction of grammatical and typographical errors, as well as adjustments to align with the reference PI, were made to the PI in DE, CS, EL, ES, FR, LV, NL, PL, PT, RO, SK, and SV. Furthermore, the MAH included a warning statement on the polysorbate threshold based on the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|